Evonik Evonik

X

Find Stenoparib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

2X-121
Also known as: 1140964-99-3, E7449, E-7449, Stenoparib, Parp inhibitor 2x-121, Unii-9x5a2qia7c
Molecular Formula
C18H15N5O
Molecular Weight
317.3  g/mol
InChI Key
JLFSBHQQXIAQEC-UHFFFAOYSA-N
FDA UNII
9X5A2QIA7C

PARP/Tankyrase Inhibitor 2X-121 is an orally available small molecule inhibitor of the nuclear enzymes poly (ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon administration, E7449 selectively binds to PARP 1 and 2, thereby preventing the repair of damaged DNA via the base excision repair (BER) pathway. This agent enhances the accumulation of single and double strand DNA breaks and promotes genomic instability eventually leading to apoptosis. PARP 1/2 inhibitor E7449 may enhance the cytotoxicity of DNA-damaging agents and of radiotherapy. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA.
1 2D Structure

2X-121

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8,11-pentaen-4-one
2.1.2 InChI
InChI=1S/C18H15N5O/c24-18-13-6-3-7-14-16(13)17(21-22-18)20-15(19-14)10-23-8-11-4-1-2-5-12(11)9-23/h1-7H,8-10H2,(H,22,24)(H,19,20,21)
2.1.3 InChI Key
JLFSBHQQXIAQEC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1C2=CC=CC=C2CN1CC3=NC4=NNC(=O)C5=C4C(=CC=C5)N3
2.2 Other Identifiers
2.2.1 UNII
9X5A2QIA7C
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 8-(isoindolin-2-ylmethyl)-2,9-dihydro-3h-pyridazino(3,4,5-de)quinazolin-3-one

2. E-7449

3. E7449

4. Parp Inhibitor 2x-121

5. Stenoparib

2.3.2 Depositor-Supplied Synonyms

1. 1140964-99-3

2. E7449

3. E-7449

4. Stenoparib

5. Parp Inhibitor 2x-121

6. Unii-9x5a2qia7c

7. 9x5a2qia7c

8. Cid 25267262

9. 2x-121

10. 11-(1,3-dihydroisoindol-2-ylmethyl)-2,3,10,12-tetrazatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaen-4-one

11. 3h-pyridazino(3,4,5-de)quinazolin-3-one, 8-((1,3-dihydro-2h-isoindol-2-yl)methyl)-1,2-dihydro-

12. Stenoparib [who-dd]

13. Schembl3886731

14. Chembl3644587

15. Schembl22023558

16. Bcp19934

17. Ex-a1282

18. Nsc783107

19. Nsc798215

20. S8419

21. Zinc59277233

22. Ccg-267668

23. Cs-3479

24. Nsc-783107

25. Nsc-798215

26. Sb16888

27. 8-(1,3-dihydro-isoindol-2-ylmethyl)-2,9-dihydro-1,2,7,9-tetraaza-phenalen-3-one

28. Ac-36842

29. Hy-12418

30. A909458

31. Q27273339

32. 8-(isoindolin-2-ylmethyl)-2,9-dihydro-3h-pyridazino[3,4,5-de]quinazolin-3-one

2.4 Create Date
2019-01-15
3 Chemical and Physical Properties
Molecular Weight 317.3 g/mol
Molecular Formula C18H15N5O
XLogP31.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count2
Exact Mass317.12766012 g/mol
Monoisotopic Mass317.12766012 g/mol
Topological Polar Surface Area69.1 Ų
Heavy Atom Count24
Formal Charge0
Complexity586
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY